Arvinas
IPO News: Filed S-1/A: Arvinas Holding Launches 6.67mm Share IPO with $14.00 - $16.00 Marketing Range
Arvinas

Arvinas Holding

NASDAQ:  ARVN

Initial Filing Date:  08/30/18

Launch Date:  09/14/18

Price Range:  $14.00 - $16.00

Shares Offered (Pre-Shoe | mm):  6.67

Primary Shares (mm):  6.67

Secondary Shares (mm):  0.0

Amount Offered (@ Midpoint)(mm):  $100.0

% Secondary:  0.0%

Shares Outstanding (mm):  31.2

Market Value at Midpoint (mm):  $467.8

Offering as % of Market Value:  21.4%

Bookrunner:  GS | CITI | PJ

Major Holders:  Canaan IX LP | 5AM Partners (Cush Parmar, Director) | Craig Crews Family Trust (Founder) | RA Capital Management (Andrew Levin, Director) | OrbiMed Capital | Nextech V Oncology | Liam Ratcliffe (Director) | Stephen Squinto (Director)

Industry:  Healthcare

Description:  Arvinas is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins.

Note:  Emerging Growth Company; This offering includes a directed share program

 

Launch Link:  S-1/A